‘å’°Šà




Col 002@FOLFIRI ô
Col 005@mFOLFOX6@ô
Col 007@IRIS@ô
Col 009@FOLFIRI+Bmab@ô
Col 011@mFOLFOX6+Bmab@ô
Col 015@CPT-11-2W@ô
Col 016@IRIS+RT
@ô
Col 017@Cmab@ô
Col 018@CPT-11+Cmab@ô
Col 019@XELOX@ô
Col 020@XELOX+Bmab@ô
Col 021@FOLFIRI+Cmab@ô
Col 022@Pmab@ôi»–ò‰ïŽÐì¬‚̃pƒ“ƒtƒŒƒbƒg‚ðŽg—pj
Col 023@FOLFIRI+Pmab@ô
Col 026@CPT-11 biweekly@ô
Col 028@SOX@ô
Col 029@SOX+Bmab@ô

Col 030@mFOLFOX6+Pmab@ô
Col 031@FOLFIRI+RAM ô
Col 032@FOLFIRI+Aflibercept@ô
Col 033@IRIS+Bmab@ô
Col 034@FOLFOXIRI+Bmab@ô
Col 035@FOLFOXIRI@ô
Col 036@XELIRI+Bmab@ô
Col 037@mFOLFOX6+Cmab@ô
Col 038@TAS102+Bmab@ô
Col 039@BRAF+MEK+Cmab@ôi»–ò‰ïŽÐì¬‚̃pƒ“ƒtƒŒƒbƒg‚ðŽg—pj
Col 040@Pertuzumab+Tmab ô@i»–ò‰ïŽÐì¬‚̃pƒ“ƒtƒŒƒbƒg‚ðŽg—pj


”畆áŠQ‘΍ôiÇó”­Œ»Žžj
”畆áŠQ‘΍ôi—\–hj

‘Oƒy[ƒW

TOPƒy[ƒW